InaphaeaBioLabs

Inaphaea BioLabs

[InaphaeaBioLabs @Inaphaea]

Inaphaea continues to drive innovation in drug development through its cutting-edge work with Patient-Derived Cells, advanced in-silico modelling, and strategic collaborations.

Read more about our latest developments on our website: https://t.co/jQAPPhqvBF

#CancerResearch

[InaphaeaBioLabs @Inaphaea]

Exclusive licence agreement struck with Dominion Biotech.

Inaphaea is pleased to announce the execution of an exclusive licence agreement with UK-based Dominion Biotech Ltd for our PredictRx® platform.

Find out more about the agreement here: https://t.co/Q4xgEQ7k11

[InaphaeaBioLabs @Inaphaea]

Over 12,000 cases of head and neck cancer are diagnosed each year.

We offer cells across our biobank of 478 Patient Derived Cancer cells, representing 66 types of cancer, including 11 head and neck PDCs across 7 subtypes (8 with RNA-seq data): https://t.co/DQwCUYL5PO

[InaphaeaBioLabs @Inaphaea]

Be sure to listen to the podcast recorded by @valirxplc and Inaphaea Director, Dr Mark Eccleston, as he speaks to Katy Barber about his career journey.

Listen here: https://t.co/aogjduxUGT

#Biotech #AssayDevelopment #BioTechBuilders #LifeSciences #DrugDevelopment

[ValirxPlcOfficial @valirxplc]

CEO Dr Mark Eccleston has recorded a podcast with Biotech Builders’ Katy Barber. In this episode, Mark speaks about his extensive background and his journey to becoming a CEO.

Listen to the podcast here: https://t.co/RFV8gVH3a5

#DrugDevelopment #LifeSciences #BiotechBuilders

[ValirxPlcOfficial @valirxplc]

Agreement struck with Ambrose Healthcare to license VAL401.

We are pleased to announce that Ambrose Healthcare, has opted to license VAL401 to support the treatment of rare and difficult-to-treat pancreatic cancer.

Find out more: https://t.co/Nul5MB5RmT

#CancerResearch #PDCs

[InaphaeaBioLabs @Inaphaea]

Inaphaea is advancing the characterisation of our most commercially promising Patient-Derived Cells (PDCs). Each model is assessed for expansion potential, growth condition optimisation, and precise cellular composition.

Find out more: https://t.co/DQwCUYL5PO

#DrugDiscovery

[InaphaeaBioLabs @Inaphaea]

At Inaphaea, we are dedicated to understanding our drug candidates during the discovery and preclinical phases of development. Our goal is to support decision-making in translational drug development for therapeutic areas within women's health.

https://t.co/X88TQjWS3e

#CSAW25

[InaphaeaBioLabs @Inaphaea]

If you're attending BIO this week, be sure to speak to Mark Eccleston, CEO of our parent company, @valirxplc.

[ValirxPlcOfficial @valirxplc]

The BIO International Convention begins today, held at the Boston Convention & Exhibition Center.

ValiRx CEO Dr Mark Eccleston will be in attendance. To connect with Mark during the convention this week, click here: https://t.co/u5yI1REjwJ

@IAmBiotech

#BIO2025 #Event

[InaphaeaBioLabs @Inaphaea]

If you're attending the 2025 @ASCO Annual Meeting, be sure to speak with Mark Eccleston, CEO of our parent company, @valirxplc.

#ASCO2025 #Event #Networking

[ValirxPlcOfficial @valirxplc]

ValiRx CEO, Dr Mark Eccleston is attending the 2025 @ASCO Annual Meeting, later this week.

Mark will be available to speak to fellow delegates about our drug pipeline and development services. To book a meeting with Mark, get in touch: https://t.co/EeAiwfTtCg

#ASCO2025

[InaphaeaBioLabs @Inaphaea]

We’re thrilled to announce that Inaphaea won the Start-Up award at the @MedilinkMids Business Awards 🏆

It’s an honour to be recognised among many innovative organisations across the Midlands. We’re proud of our progress & we’re looking forward to what lies ahead. #MMBizAwards25

[InaphaeaBioLabs @Inaphaea]

Be sure to watch the latest video by Inaphaea's Director, Mark Eccleston, as he speaks about Pro-Senescence cancer therapeutics.

#Assays #CancerCellAssays #BioTech #LifeSciences #AssayDevelopment #DrugDiscovery

[ValirxPlcOfficial @valirxplc]

Mark Eccleston, CEO, discusses Pro-Senescence cancer therapeutics.

He explores the science behind the approach, as well as partnerships, funding, and repurposing existing drugs via evaluation agreements. Watch below!

https://t.co/zeQYNiR3ee
#CancerResearch #DrugDiscovery #val

[InaphaeaBioLabs @Inaphaea]

At Inaphaea, we offer cells for purchase and testing services across our biobank of 478 Patient Derived Cancer cells, representing 66 types of cancer, including testicular cancer.

Find out more: https://t.co/gPBPpLrVCY

#TesticularCancerAwarenessMonth #CancerResearch

[InaphaeaBioLabs @Inaphaea]

Learn more about our cell-based assays and services here: https://t.co/gPBPpLrnNq

#BowelCancerAwarenessMonth #CancerResearch #AssayDevelopment #DrugDevelopment #CancerAwareness

[InaphaeaBioLabs @Inaphaea]

At Inaphaea, we offer cells for purchase and testing services across our biobank of 478 Patient Derived Cancer cells, representing 66 types of cancer, including 54 Colorectal PDCs, 32 of which have RNA-seq data.

[InaphaeaBioLabs @Inaphaea]

We're looking forward to attending the @OneNucleus BioWednesday London - Ones to Watch event this evening at London’s Queen Mary Innovation Centre.

To connect with Inaphaea's Head of Strategic Commercial Development, Dr Andrew Carnegie, contact us here: https://t.co/l0LVvKQB55

[InaphaeaBioLabs @Inaphaea]

Inaphaea BioLabs Director Mark Eccleston is attending and presenting at the 4th Ace Drug Discovery Summit in London next week.

Mark's talk will be centred on Oncolytic Peptides - Novel Agents For Neoantigen Release on 2 April at 4pm.

[ValirxPlcOfficial @valirxplc]

ValiRx CEO Mark Eccleston and Director of Research Michelle Barnard are attending the 4th Ace Drug Discovery Summit in London next week.

Be sure to catch Mark’s talk on 2 April at 4pm.

#4thADDSLondon #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking

[InaphaeaBioLabs @Inaphaea]

Great to see Inaphaea Director and CEO of our parent company, @valirxplc featured in @inspiratio29631.

Read more here: https://t.co/YRpeJZIIuw

#Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch

[ValirxPlcOfficial @valirxplc]

ValiRx CEO Dr Mark Eccleston featured in The Inspirational Leaders magazine.

Mark's commitment to accelerating early-stage drug development is a testament to the leadership needed to bring drug candidates to the clinic.

@inspiratio29631

Read more: https://t.co/B6jz0axFoy

[InaphaeaBioLabs @Inaphaea]

Great to see Michelle Barnard, Director of Research at our parent company, @valirxplc attend the Women's Health Endometriosis Event at @UoDLifeSciences.

@DDU_Dundee

#EndometriosisAwarenessMonth #Assays #ScientificResearch #DrivingInnovation

[ValirxPlcOfficial @valirxplc]

Our Director of Research, Michelle Barnard is attending the Women's Health Endometriosis Event at @UoDLifeSciences to discuss approaches to drug discovery and development of Endometriosis therapeutics including ValiRx’s VAL301.

Find out more about VAL301: https://t.co/kRgvD3IAHy

[InaphaeaBioLabs @Inaphaea]

The @EBDgroup BIO-Europe Spring conference begins today.

Dr Mark Eccleston, CEO of our parent company, @valirxplc, will attend and speak to fellow delegates about Inaphaea's services.

To book a meeting with Mark, please get in touch: https://t.co/l0LVvKQB55

#BIOEuropeSpring

[InaphaeaBioLabs @Inaphaea]

This recognition reflects our team's dedication to innovation in the life sciences sector. We're thrilled to be considered alongside other outstanding businesses and look forward to the awards ceremony on 15 May.

#MMBizAwards25 #Assays #PatientDerivedCells

[InaphaeaBioLabs @Inaphaea]

We're delighted to announce that Inaphaea BioLabs has been shortlisted in the Start-Up category for the @MedilinkMids Business Awards!